Our mission is to create and lead cross-sector efforts that validate and qualify biomarkers and other drug development tools to accelerate better decision making for the development of new therapeutics and health technologies.

The Biomarkers Consortium (BC) convenes government, industry, patients and patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogates.

The core operations of the Biomarkers Consortium are supported through contributing membership. Organizations representing private industry (including the pharmaceutical, biotechnology, diagnostics, and information technology industries) and not-for-profit organizations (including associations, advocacy groups, trade organizations, and philanthropic organizations) that wish to support biomarkers development are eligible to become contributing members.

Join the Biomarkers Consortium
  • 14

    Therapeutics Advanced

  • 1

    Clinical Safety Biomarker Qualification

  • 6

    FDA guidance documents

  • 9

    Clinical Tools Used In Drug Development

  • 800+


Videos + Webinars

How To Develop and Qualify Biomarkers: Biomarker Consortium Perspective
Beta Cell Project "A New Tool for Diabetes Research"
FNIH Highlights Success of the ABC-CT Program in Advancing Neuropsychiatric Biomarkers for Autism
VOL-PACT: A Novel Cancer Imaging Project

Partner With Us